Modelling the pharmacokinetics of tramadol: On the difference between CYP2D6 extensive and poor metabolizers

Journal of Theoretical Biology

Volumn 254, Issue 3, 2008, Pages 568-574

  Di Patti, F ^a   Fanelli, D ^a   Pedersen, R S ^b   Giuliani, C ^c   Torricelli, F ^c  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Drug metabolism; Genetic polymorphisms; O desmethyltramadol; Pain therapy and experiments; Personalized medicine

Indexed keywords

CYTOCHROME P450 2D6; TRAMADOL;

BLOOD; DRUG; INJURY; MEDICINE; METABOLISM; METABOLITE; NUMERICAL MODEL; POLYMORPHISM; TIME SERIES;

ARTICLE; DEMETHYLATION; DRUG DIFFUSION; DRUG ELIMINATION; DRUG METABOLISM; GENETIC POLYMORPHISM; MATHEMATICAL MODEL; METABOLITE; METHYLATION; PRIORITY JOURNAL; STEREOCHEMISTRY;

ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; DIFFUSION; HUMANS; INFUSIONS, INTRAVENOUS; MODELS, CHEMICAL; PAIN; POLYMORPHISM, GENETIC; TRAMADOL;

EID: 51349115005     PISSN: 00225193     EISSN: 10958541     Source Type: Journal    
DOI: 10.1016/j.jtbi.2008.06.005     Document Type: Article

References (24)

1. Abdel-Rahman S.M., Leeder J.S., Wilson J.T., Gaedigk A., Gotschall R.R., Medve R., Liao S., Spielberg S.P., and Kearnset G. Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J. Clin. Pharm. 42 (2002) 24-29
2. Daly A.K., Leathart J.B.S., London S.J., and Idle J.R. An inactive cytochrome-p450 CYP2D6 allele containing a deletion and a base substitution. Hum. Genet. 95 (1995) 337-341
3. Eichelbaum M., Ingelman-Sundberg M., and Evans W.E. Pharmacogenomics and individualized drug therapy. Annu. Rev. Med. 57 (2005) 119-137
4. Evert B., Griese E.U., and Eichelbaum M. Cloning and sequencing of a new nonfunctional CYP2D6 allele-deletion of T-1795 in exon-3 generates a premature stop codon. Pharmacogenetics 4 (1994) 271-274
5. Gillen C., Haurand M., Kobelt D.J., and Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human μ-opioid receptor. Naunyn-Schmiedeberg's Arch. Pharm. 362 (2000) 116-121
6. Gough A.C., Miles J.S., Spurr N.K., Moss J.E., Gaedigk A., Eichelbaum M., et al. Identification of the primary gene defect at the cytochrome-P450 CYP2D locus. Nature 347 (1990) 773-776
7. Grond S., and Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 43 (2004) 879-923
8. Guttmacher A.E., and Collins F.S. Inheritance and drug response. N. Engl. J. Med. 348 (2003) 529-537
9. ′ splice recognition site. Am. J. Hum. Genet. 47 (1990) 994-1001
10. Kagimoto M., Heim M., Kagimoto K., Zeugin T., and Meyer U.A. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J. Biol. Chem. 265 (1990) 17209-17214
11. Katzung B.G. Basic & Clinical Pharmacology (2003), McGraw-Hill Medical, New York
12. Lötsch J., Weiss M., Kobal G., and Geisslinger G. Pharmacokinetics of morphine-6-glucuronide and its formation from morphine after intravenous administration. Clin. Pharm. Ther. 63 (1998) 629-693
13. Luan P.G., and Kao Y.M. Drifting diffusion on a circle as a continuous limit of a multiurn Ehrenfest model. Phys. Rev. E 69 (2004) 022102
14. Marez D., Legrand M., Sabbagh N., Guidice J.M.L., Spire C., Lafitte J.J., et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7 (1997) 193-202
15. Mikus G., and Weiss J. Influence of CYP2D6 genetics on opiod kinetics, metabolism and response. Curr. Pharmacogenetics 3 (2005) 43-52
16. Paar W.D., Frankus P., and Dengler H.J. The metabolism of tramadol by human liver microsomes. J. Mol. Med. 70 (1992) 708-710
17. Pedersen R.S., Brosen K., and Nielsen E. Enantioselective HPLC method for quantitative determination of tramadol and O-desmethyltramadol in plasma and urine: application to clinical studies. Chromatographia 57 (2003) 279-285
18. Pedersen R.S., Damkier P., and Brøsen K. Enantioselective pharmacokinetics of tramadol in CYP2D6 extensive and poor metabolizers. Eur. J. Clin. Pharm. 62 (2006) 513-521
19. Saxena R., Shaw G.L., Relling M.V., Frame J.N., Moir D.T., Evans W.E., et al. Identification of a new variant CYP2D6 allele with a single-base deletion in exon-3 and its association with the poor metabolizer phenotype. Hum. Mol. Genet. 3 (1994) 923-926
20. Stamer U.M., Bayerer B., and Stüber F. Genetics and variability in opioid response. Eur. J. Pain 9 (2004) 101-104
21. Subrahmanyaam V., Renwick A.B., Walters D.G., Young P.J., Price R.J., Tonelli A.P., and Lake B.G. Identification of cytochrome P-450 isoforms responsible for cis-tramadol metabolism in human liver microsomes. Drug Metab. Dispos. 29 (2001) 1146-1155
22. Tyndale R., Aoyama T., Broly F., Matsunaga T., Inaba T., Kalow W., et al. Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281-possible association with the poor metabolizer phenotype. Pharmacogenetics 1 (1991) 26-32
23. Weiss M. Analysis of metabolite formation pharmacokinetics after intravenous and oral administration of the parent drug using inverse Laplace transformation. Drug Metab. Dispos. 26 (1998) 562-565
24. Wu W.N., Mckown L.A., and Liao S. Metabolism of the analgesic drug ULTRAM (R) (tramadol hydrochloride) in humans: API-MS and MS/MS characterization of metabolites. Xenobiotica 32 (2002) 411-425